The EUA for bamlanivimab is in effect for the duration of the COVID-19 declaration justifying emergency use of these products, unless terminated or revoked (after which the product may no longer be used). Literature issued November 2020 Eli Lilly and Company, Indianapolis, IN 46285, USA Copyright © 2020, Eli Lilly and Company. All rights reserved. 5.0-BAM-0000-EUA PAT-20201109 3 Reference ID: 4699500

FDA Letter of Authorization - Page 34 FDA Letter of Authorization Page 33 Page 35